BioAge Labs Posts $33.5 Million Quarterly Loss As BGE-102 Trial Costs Climb, With Heart Data Due This Quarter
The biotech says its $352.3 million in cash and securities should fund operations through 2029, based on its current operating plan.
BioAge Labs, a clinical-stage drug developer that targets the biology of human aging, reported a third-quarter net loss of $33.5 million, or $0.73 per share, up from $20.2 million, or $0.56 per share, a year earlier. Costs for its lead drug BGE-102 drove the increase, and topline data from a cardiovascular trial are due in the fourth quarter, the company said Thursday.
Trial costs drive the wider loss
Research and development spending rose to $30.2 million from $18.5 million, according to the 8-K. The main driver was a $13.2 million increase in direct BGE-102 costs, covering the QUELL-CV and QUELL-DME trials and drug manufacturing. Personnel costs added $1.7 million, on higher headcount and stock pay from new option grants, while direct costs for other programs fell $3.3 million.
Collaboration revenue fell to $0.3 million from $2.1 million. The company attributed most of the $1.8 million drop to a $1.7 million cumulative catch-up adjustment tied to a September amendment of its Novartis agreement, which added $0.9 million of research funding and widened the research work.
General and administrative expenses were $7.5 million, against $6.7 million a year earlier, mainly on stock-based pay for new option grants.
Cash lasts through 2029
BioAge held about $352.3 million in cash, cash equivalents and marketable securities at September 30. Based on its current operating plan, it estimates that is enough to fund operations and capital expenses through 2029.
The company is a clinical-stage biopharmaceutical firm, meaning its drugs are still in trials. BGE-102 is an oral drug that blocks NLRP3, a protein the company describes as a switch that turns on inflammation. BioAge is also developing drugs aimed at the APJ receptor for obesity, and it works with Novartis and Lilly on earlier-stage programs.
Two trials, two readouts
QUELL-CV, a placebo-controlled mid-stage trial of 30 mg, 60 mg and 90 mg daily doses in about 160 adults with obesity and elevated inflammation, has finished enrolling. Its main goal is the change in hsCRP, an inflammation marker, over 12 weeks, with topline data expected in the fourth quarter of 2026.
QUELL-DME, a mid-stage trial in about 180 people with diabetic macular edema, an eye disease, dosed its first participant in September. Topline results are expected in the second half of 2027.
CEO Kristen Fortney said the trial's main goal, change in best-corrected visual acuity, is the one used to approve existing therapies, so a positive result "could support a streamlined path into a pivotal trial." BioAge also intends to file its first investigational new drug application for an APJ program by year-end 2026.
The fourth-quarter QUELL-CV readout is the next test, and the company expects it to inform the best dose of BGE-102.
Sources
- 8-K Filing — BioAge Labs, Inc. (BIOA) — SEC EDGAR
- Exhibit bioa-ex99_1.htm — BioAge Labs, Inc. 8-K exhibit — SEC EDGAR
- BioAge Labs, Inc. (BIOA) Stock Price, News, Quote & History - Yahoo Finance — Yahoo Finance
- BioAge Labs Reports Third Quarter 2026 Financial Results — globenewswire.com